Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
5 stopped studies mapped to BCLC Stage B Hepatocellular Carcinoma and descendants · 100% state a reason
Over the 5 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed… | Phase 2 | terminated | Jan 20, 2022 | Academic and Community Cancer Research United | Sponsor has withdrawn support for the study. | Other (stated, no rule matched) |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Phase 2 | terminated | Mar 20, 2023 | Yale University | Low enrollment | Enrollment / accrual |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Early Phase 1 | terminated | Mar 2, 2021 | Jonsson Comprehensive Cancer Center | Withdrawn by sponsor | Other (stated, no rule matched) |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of… | Phase 2 | withdrawn | Apr 14, 2022 | OHSU Knight Cancer Institute | Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending… | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 4, 2026source: clinicaltrials